In a Phase 2 trial, RTB-101 alone and RTB-101 plus everolimus showed a signal, leading to the decision to proceed with RTB-101 alone in the pivotal trial.

“there were actually three studies so this the the study where rtb 101 was used alone was actually the the third and that was their pivotal clinical Tri there was a second phase 2 in between the 2014 paper and the the pivotal where they used a combination of ever align us with rtb 101 and I you know I wasn't I wasn't in the room so I don't know exactly what went into the thought process of why use rtb 101 I've been told there are probably at least two factors that played in one was that in cell culture models there was some data that rtb 101 induced antiviral gene expression so there was some you know at least somewhat plausible biological rationale for for the end point that they were going after which was if I remember correctly at least for the pivotal it wasn't so much vaccine response it was subsequent infections and so the the thought was if you can both boost vaccine response and enhance uh resistance to subsequent infections that might be a combination that was that was useful so in the second phase 2 the rtb 10 1 showed a signal the rtb 101 plus ever alyus also showed a signal but rtb 101 alone showed a signal”

“so in the second phase 2 the rtb 10 1 showed a signal the rtb 101 plus ever alyus also showed a signal but rtb 101 alone showed a signal so the decision was made to go to the pivotal with rtb 101 alone”